Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: Multicenter, double blind, randomized, controlled trial in mainland China

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Xu, Jing ^a   Zhang, Yi Xiang ^a   Yu, Xue Qing ^b   Liu, Zhi Hong ^c   Wang, Li Ning ^d   Chen, Jiang Hua ^e   Fan, Ya Ping ^f   Ni, Zhao Hui ^g   Wang, Mei ^h   Yuan, Fa Huan ⁱ   Ding, Guo Hua ^j   Chen, Xiang Mei ^k   Zhang, Ai Ping ^l   Mei, Chang Lin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f NANTONG MEDICAL COLLEGE   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

ⁱ THIRD MILITARY MEDICAL UNIVERSITY   (China)

^j RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^k CHINESE PLA GENERAL HOSPITAL   (China)

^l JINAN MILITARY GENERAL HOSPITAL   (China)

more..

Author keywords

Chronic kidney disease 5D; Continuous ambulatory peritoneal dialysis (CAPD); Hemodialysis; Hyperphosphatemia; Lanthanum carbonate

Indexed keywords

CALCIUM; LANTHANUM CARBONATE; PHOSPHORUS; PLACEBO; SEVELAMER;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD SAMPLING; BRAIN INFARCTION; CALCIUM BLOOD LEVEL; CHINA; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMPUTER SYSTEM; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PERITONITIS; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM; SIDE EFFECT; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT DURATION; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; CHINA; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; MALE; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873199553     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-29     Document Type: Article

References (37)

1. Oral phosphate binders in patients with kidney failure. Tonelli M, Pannu N, Manns B, N Engl J Med 2010 362 1312 1324 10.1056/NEJMra0912522 20375408
2. Serum phosphate levels and mortality risk among people with chronic kidney disease. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL, J Am Soc Nephrol 2005 16 520 528 10.1681/ASN.2004070602 15615819 (Pubitemid 41725150)
3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK, Am J Kidney Dis 2008 52 519 530 10.1053/j.ajkd.2008.03.020 18514987
4. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR, Kidney Int 2006 70 351 357 10.1038/sj.ki.5001542 16738536 (Pubitemid 44086585)
5. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
6. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK, J Am Soc Nephrol 2001 12 2131 2138 11562412 (Pubitemid 32880350)
7. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M, Am J Kidney Dis 2004 44 34 38 15486872
8. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Am J Kidney Dis 1998 31 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176
9. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 1 S202 14520607
10. Phosphorus binders and survival on hemodialysis. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M, J Am Soc Nephrol 2009 20 388 396 10.1681/ASN.2008060609 19092121
11. Oral phosphate binders. Hutchison AJ, Kidney Int 2009 75 906 914 10.1038/ki.2009.60 19279554
12. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Schaefer K, Umlauf E, von Herrath D, Am J Kidney Dis 1992 19 460 464 1585935
13. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Miller JE, Kovesdy CP, Norris KC, Mehrotra R, Nissenson AR, Kopple JD, Kalantar-Zadeh K, Am J Nephrol 2010 32 403 413 10.1159/000319861 20814200
14. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF, Am J Kidney Dis 2009 54 619 637 10.1053/j.ajkd.2009.06.004 19692157
15. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT, Nephrol Dial Transplant 2009 24 3168 3174 10.1093/ndt/gfp350 19622572
16. LAM-302 Study Group: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Joy MS, Finn WF, Am J Kidney Dis 2003 42 96 107 10.1016/S0272-6386(03)00554-7 12830461 (Pubitemid 36807658)
17. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Chiang SS, Chen JB, Yang WC, Clin Nephrol 2005 63 461 470 15960148
18. Lanthanum Carbonate Research Group: Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Shigematsu T, Ther Apher Dial 2008 12 55 61 10.1111/j.1744-9987.2007.00541.x 18257813 (Pubitemid 351197453)
19. Lanthanum Carbonate Group: Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Shigematsu T, Clin Nephrol 2008 70 404 410 19000540
20. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Al-Baaj F, Speake M, Hutchison AJ, Nephrol Dial Transplant 2005 20 775 782 10.1093/ndt/gfh693 15703206 (Pubitemid 40520656)
21. Scientific publications in nephrology and urology journals from Chinese authors in East Asia: a 10-year survey of the literature. Xu J, Mao ZG, Kong M, Hu LH, Ye CY, Xu CG, Rong S, Sun LJ, Wu J, Dai B, Chen DP, Zhu YX, Zhang YX, Zhang YQ, Zhao XZ, Mei CL, PLoS One 2011 6 14781 10.1371/journal.pone.0014781 21494662
22. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH Harmonised tripartite guideline. Statistical principles for clinical trials E9. Current Step 4 version 1998
23. Opportunities for a chronic disease outreach program in China. D'Amico G, Kidney Int 2005 68 46 S48
24. Launch of the health-care reform plan in China. Zhu C, Lancet 2009 373 1322 1324 10.1016/S0140-6736(09)60753-4 19376436
25. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Martin P, Wang P, Robinson A, Poole L, Dragone J, Smyth M, Pratt R, Am J Kidney Dis 2011 57 700 706 10.1053/j.ajkd.2010.11.028 21354682
26. Frequent Hemodialysis Network Trial Group: Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Daugirdas JT, Finn WF, Emmett M, Chertow GM, Semin Dial 2011 24 41 49 10.1111/j.1525-139X.2011.00849.x 21338393
27. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM, Curr Med Res Opin 2007 23 3167 3175 10.1185/030079907X242719 17991307
28. Lanthanum carbonate. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ, Ann Pharmacother 2006 40 234 240 10.1345/aph.1G224 16449551 (Pubitemid 43269853)
29. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Damment SJ, Pennick M, Clin Pharmacokinet 2008 47 553 563 10.2165/00003088- 200847090-00001 18698878
30. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W, Clin J Am Soc Nephrol 2009 4 178 185 10.2215/CJN.02830608 19056618
31. Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Finn WF, Joy MS, Hladik G, Clin Nephrol 2004 62 193 201 15481851 (Pubitemid 39236623)
32. SPD405-307 Lanthanum Carbonate Study: SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC, Clin Nephrol 2008 70 284 295 18826853
33. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME, Kidney Int Suppl 2003 85 73 S78 12753271
34. SPD405-309 Lanthanum Study Group: SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, Nephron Clin Pract 2008 110 15 c23 10.1159/000149239 18667837
35. SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Altmann P, Barnett ME, Finn WF, Kidney Int 2007 71 252 259 10.1038/sj.ki.5001932 17035945 (Pubitemid 46160926)
36. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG, Nephrology 2011 16 290 298 10.1111/j.1440-1797.2010.01412.x 21342323
37. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese PC, Persy V, Nephrol Dial Transplant 2009 24 1790 1799 10.1093/ndt/gfn737 19144999